UB-621 clinical trials
Also written UB-621.
How each study uses UB-621 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the UB-621 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- UB-621
- 3
Studies by the year they started
4 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
United BioPharma (2) · UBP Greater China (Shanghai) Co., Ltd (2)
Studies
Open first, then newest update. How each study uses UB-621 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital HerpesNot yet recruitingPhase 2UBP Greater China (Shanghai) Co., LtdNCT04979975Written as UB-621 low-dose
- A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621Status unknownPhase 2United BioPharmaNCT03595995Written as UB-621
- UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the GenitalsStatus unknownPhase 2UBP Greater China (Shanghai) Co., LtdNCT04714060Written as UB-621
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy VolunteersCompletedPhase 1United BioPharmaNCT02346760Written as UB-621